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Objective: The purpose of this study was to compare
health-care resource utilization and outcomes among chil-
dren treated for low-risk febrile neutropenia (FN) in a
hospital-based setting with those treated in a home-
care-based setting.
Methods: The perspective of this retrospective, cohort
study was the health payer. We collected health-care 
utilization and treatment outcome data from medical
records of 63 children (26 boys and 37 girls) with low-
risk, chemotherapy-induced FN who were treated at the
University of Arizona (27 children, the hospital-based
group) and University of New Mexico (36 children, the
home-care-based group). We identiﬁed 144 FN episodes
(72 episodes in each group). Health-care utilization
included physician visits, home-care visits, laboratory
visits, outpatient visits, hospital days, intensive care unit
days, medical tests and studies, and medications used to
manage FN (e.g., ﬁlgrastim, antimicrobials, and ancilliary
drugs and supplies). We applied uniform charges, based
on those used at the University of New Mexico in 1998.
We collected outcomes of the FN treatment (success vs.
failure and time to resolution, deﬁned as number of days
of antibiotic therapy). Rates of positive blood cultures
during treatment were also compared. Data were ana-
lyzed using nonparametric Mann–Whitney U tests for
continuous data and chi-square analysis for categorical
data. Sensitivity analyses were conducted by varying the
amount of total resource utilization, as well as utilization
of speciﬁc health-care resources.
Results: There was no difference in outcome; all episodes
of treatment in both groups resulted in successful recov-
ery from FN. Time to resolution of FN was 8.3 ± 2.7 days
for home-care FN episodes versus 7.3 ± 3.6 days for hos-
pital FN episodes (P = .064). Median charge per FN
episode was signiﬁcantly (P < .001) greater when
managed in the hospital compared to home care ($9392
vs. $5893). There was greater use of laboratory and radi-
ographic studies in the hospital-based patients (P < .01).
However, children in the home-care-based group were
more often treated with granulocyte colony-stimulating
factor (ﬁlgrastim, median charge $1085 vs. $451,
P < .001), and median antibiotic charges were higher
($2523 vs. $1526, P < .001). Positive blood cultures were
more common among the hospital-based FN treatments
(30.6 vs. 11.1%, P = .012).
Conclusions: We found that management of low-risk FN
in a home-care-based setting was associated with signiﬁ-
cantly lower median total charges with no differences in
outcome.
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ABSTRACT
Introduction
The management of myelosuppression in children
with cancer has become increasingly important with
the advent of dose-intensive chemotherapeutic 
regimens [1]. Chemotherapy-induced febrile neu-
tropenia (FN) requires the prompt initiation of
broad-spectrum antibiotics to prevent serious mor-
bidity [2,3]. Children with FN have usually been
hospitalized for treatment with intravenous antibi-
otics [4,5]. However, recent advances in antibiotic
regimens and home-care infusion programs, as 
well as the availability of colony-stimulating
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factors, have made home-care-based management
of FN a possibility [6–8]. Early hospital discharge,
even complete home-care-based management, has
been shown effective for patients with low-risk FN
[7–14].
The health-care resources utilized for the man-
agement of chemotherapy-induced FN in children
are considerable. To date there are no published
economic and resource use comparisons of pediatric
FN management in home-care versus hospital set-
tings. Home-care-based FN management may
improve health-related quality of life, decrease
nosocomially acquired infection rates, and reduce
health-care costs, but evidence of these outcomes
has not been established. Our purpose was to
compare health-care utilization and outcomes
resulting from the treatment of FN in these two 
settings.
Methods
Approval for this study was obtained from the hos-
pital’s institutional review board. The perspective of
this study was the health payer. This was a retro-
spective two-group cohort comparison. Health-care
utilization and charges from low-risk FN episodes
of patients managed at two pediatric oncology
centers were compared. Low-risk FN episodes were
deﬁned using published exclusion criteria [15,16].
The exclusions were patients who: 1) had chronic
neutropenia; 2) developed FN as inpatients; 3) had
inadequate control of their underlying cancer;
and/or 4) demonstrated serious concurrent comor-
bidity at FN presentation or during an initial FN
treatment observation period. Serious comorbidi-
ties included severe infection-related instability,
hypotension (deﬁned as diastolic blood pressure
greater than 20 mmHg below baseline), need for
pressor agents, altered mental status, respiratory
failure, or clinical signs of shock, including signs of
insufﬁcient end-organ perfusion. All consecutive
episodes meeting criteria for low-risk FN at each
site were included.
Study Sites
Both study sites were university-based centers 
that treated the majority of pediatric oncology
patients in their respective states. Both centers 
were members of the Pediatric Oncology Group
(POG), and adhered to POG treatment protocols.
However, the centers differed in their usual practice
for management of low-risk FN; University of
Arizona Medical Center (UAMC) employed the
hospital setting and University of New Mexico
Children’s Hospital (UNM) employed the home-
care setting.
Data for hospital-based FN episodes were col-
lected from UAMC from all low-risk FN patients
managed consecutively between December 1994
and June 1997. Some UAMC patients in our study
were discharged to home care before completion 
of antibiotic therapy and received the remainder 
of their FN treatment through home care. Data for
these patients included the home-care portion of
their treatment.
The home-care-based comparison group
included all low-risk FN episodes managed consec-
utively at UNM between October 1990 and May
1997. Requirements for home-care-based manage-
ment of FN were 24 hour availability of a parent
or legal guardian and residence within 1- hour
surface travel of UNM. The parent or guardian was
obligated to maintain daily contact with the home-
care agency and/or the pediatric oncology team.
The initial doses of antibiotics were administered
under observation at the emergency room or pedi-
atric clinic. Patients were discharged to home care
when vital signs and exam were deemed stable,
usually within 1 to 3 hours.
Subjects
Clinical inclusion criteria were age 1 to 19 years,
absolute neutrophil count (ANC) of <500/ml, and 
a temperature of 38.3°C. Subjects were excluded if
they were not considered low-risk FN, as deﬁned
above [15,16]. Patients were also excluded if: 1) the
FN episode was immediately subsequent to induc-
tion chemotherapy for a newly diagnosed acute
leukemia; 2) their ANC before the initiation of
chemotherapy was less than or equal to 500/ml; (3)
they had received autologous or allogeneic stem cell
support; or (4) they had received radiation therapy
to a signiﬁcant fraction of the bone marrow com-
partment. A physical exam of each patient was 
performed by a pediatric hematologist/oncologist
familiar with the patient’s history and diagnosis. All
patients had various central venous catheters.
Treatment Process
The UAMC patients received pre-FN chemotherapy
in the hospital. UNM patients received their pre-FN
chemotherapy through an established home-care
program [17]. At the physician’s discretion, patients
in both groups received ﬁlgrastim (5mg/kg/day) 
as a prophylactic agent before the FN episode. A 
complete blood count with differential, blood cul-
tures from central lines and/or peripheral veins, 
and initiation of broad-spectrum antibiotic therapy
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were performed in accordance with currently 
published recommendations [5,18–20]. Chest radi-
ographs were obtained at the discretion of the 
evaluating physician. The clinical end points were
resolution of fever and neutropenia and discon-
tinuation of broad-spectrum antibiotic therapy.
Health-care resource data collection began with the
ﬁrst dose of antibiotics and ended with the clinical
end point.
Design, Data Handling, and Calculation of 
Monetary Charges
A standardized data acquisition form was com-
pleted for each FN episode. Demographic data
included age, sex, oncology diagnosis, preceding
chemotherapy course, ANC at antibiotic initiation,
and ANC upon discontinuation of antibiotics or
discharge from the hospital. Health-care utiliza-
tion included antibiotics, supportive medication,
number of hospital days, number of intensive care
unit days, physician visits, outpatient visits, emer-
gency room visits, home-care visits, diagnostic tests,
and laboratory tests. Data for each FN episode were
collected directly from patient charts.
Each health-care resource was assigned a charge
value based on 1998 usual and customary charges
at the UNM Children’s Hospital or, for home-care
visits, local home-care health agencies providing FN
treatments. The total charge for each health-care
resource was calculated by multiplying the utiliza-
tion of each resource for each episode by appropri-
ate charge values. Total charges per episode were
determined by adding all charges for each resource.
Drug charges were based upon standard milligram
per kilogram dosages. Filgrastim charges were
limited to those administered during the FN
episode; charges for ﬁlgrastim administered for pre-
vention of FN were not included.
Statistical Analysis
To compare demographic data and outcome data
we used Student’s t tests for continuous data and
chi-square analyses for categorical data. We per-
formed three planned analyses of health-care uti-
lization and charge data. The primary analysis
included all episodes of FN treatment, with FN
episode as the unit of analysis. The second analysis
was performed using mean charges per patient,
because some patients were treated for more than
one episode of FN. Thus, in the second analysis, the
patient was the unit of analysis. The third analysis
was limited to those episodes during which ﬁlgras-
tim was used, with FN episode as the unit of 
analysis. Because charge data were skewed, non-
parametric Mann–Whitney U tests were used to
compare median charges. The a priori level of sta-
tistical signiﬁcance was alpha = .05.
Sensitivity Analysis
Our sensitivity analysis involved applying measured
variations in total direct medical charges and in
charges for resources constituting high percentages
of total charges. In addition, charges representing
practice pattern variations between the two groups
were varied, speciﬁcally antibiotic, laboratory, and
ﬁlgrastim charges. Furthermore, charges for these
resources were removed from total charges to
display the relative impact of the practice pattern
variations.
The sensitivity analyses were based on median
charges per episode. For measures of variability we
used upper and lower quartile values, which reﬂect
the amount that 25% of all episodes are above or
below. Sensitivity analysis focused on comparisons
of charges for FN treatment in the two settings,
with home-care charges increased to the upper
(75%) quartile and hospital charges decreased to
the lower (25%) quartile. A break-even analysis
was performed to identify the decreases in number
of hospital days and percentage of hospital charges
that would result in charges equal to the home-
care-based group.
Results
Records were retrospectively collected from 27
children (72 FN episodes) who received hospital-
based FN management and 36 children (72 FN
episodes) who received home-care-based FN man-
agement. Illness, demographic variables, use of ﬁl-
grastim, and level of neutropenia were compared
between the two groups (Table 1). The three most
common FN-inducing chemotherapy regimens in
the hospital-based cohort were alkylator-based
(24%), antimetabolite-based (22%) and alkyla-
tor/anthracycline combinations (12.5%), while for
the home-care-based cohort, the regimens were
alkylator/epipodphyllotoxin-based (32%), alkyla-
tor/anthracycline combinations (31%), and alkyla-
tor-based (12.5%). All chemotherapy regimens
induced bone marrow depression severe enough to
warrant the use of prophylactic ﬁlgrastim in the
majority of children, with a mean ANC < 100/ml at
the time of FN in both groups. The use of ﬁlgras-
tim was signiﬁcantly higher in the home-care-based
group (P < .05) and the ﬁnal ANC was higher for
the home-care-based group (Table 1). This ﬁnding
was associated with timing of the ﬁnal ANC, which
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was performed at discharge for hospital-based
patients, which for several patients was before com-
pletion of antibiotic therapy.
Patient outcomes and health resource utilization
between the two study groups were compared
(Table 2). There were no signiﬁcant differences in
recovery rates, clinical deterioration requiring
intensive care support, or time to resolution of
infectious symptoms and neutropenia, deﬁned 
as total number of days of antibiotic therapy
(P = .064). Patients managed in home-care settings
had a mean of 1.3 additional days of intravenous
antibiotic use (P = .008). Children treated in the
hospital-based group spent a median of 6 days in
Table 1 Patient group comparisons: disease types, demographic and treatment variables, and severity of neutropenia
Characteristic Hospital-based (UAMC) Home-care-based (UNM)
Disease types*
Acute lymphoblastic leukemia 8/16 6/6
Acute myelogenous leukemia 2/6 4/7
Non-Hodgkin’s lymphoma 2/7 0/0
Brain tumors 1/1 2/2
Neuroblastomas 6/17 2/2
Sarcomas 8/25 20/51
Other solid tumors 0/0 2/4
Demographic and treatment variables
Sex (male/female)* 8/19 18/18
Age range (median) 1–18 (9) 1–18 (10)
Episodes with ﬁlgrastim 42† 58†
Absolute neutrophil count
Initiation‡
All episodes 97 ± 153 (17) 47 ± 137 (0)
Filgrastim episodes 111 ± 173 (17) 45 ± 140 (0)
Resolution‡
All episodes 1870 ± 2268 (919)§ 4737 ± 4618 (3887)§
Filgrastim episodes 2525 ± 2632 (1430)§ 5387 ± 4660 (4447)§
*Number of patients/episodes.
†Signiﬁcantly different, P < .05.
‡Mean ± SD (median).
§Signiﬁcantly different, P < .01. Patients with hospital-based treatments received last absolute neutrophil count upon discharge to home care, several days before
discontinuance of antibiotic. Patients with home-care-based treatments received last absolute neutrophil counts upon discontinuance of antibiotic.
Table 2 Health-care resource utilization and patient outcomes comparisons
Hospital-based Home-care-based 
treatment (UAMC) treatment (UNM)
Health-care resource variables Mean (SD) Median Mean (SD) Median
Blood cultures 1.7 (0.5)* 2 1.9 (0.3)* 2
All cultures 4.7 (2.0)† 4 3.4 (0.7)† 3
Microbiology studies 3.3 (2.3)† 3 1.5 (0.7)† 1
Complete blood counts 6.1 (3.0)‡ 6 4.4 (1.6)‡ 4
Platelet counts 6.0 (3.0)§ 6 4.5 (1.7)§ 4
Manual differentials 5.8 (3.0)§ 5 4.4 (1.6)§ 4
Serum chemistries 3.0 (2.8)† 2 1.0 (1.2)† 1
Clinic visits 0.5 (0.5)† 0 1.7 (1.3)† 2
Home-care days 2.3 (3.2)† 0 7.1 (2.8)† 7
Hospital days 6.4 (3.1)† 6 0.1 (0.5)† 0
Physician visits 6.6 (3.3)† 6 1.0 (1.0)† 1
Six-pack platelet transfusions 0.9 (1.0) 1 0.7 (1.1) 1
PRBC transfusions 1.4 (1.3)|| 1 0.9 (1.1)|| 0
TPN days 1.5 (2.9)† 0 0.2 (1.5)† 0
Patient outcome variables
Intensive care unit days 0 (0.1) 0 0.1 (0.5) 0
Intravenous antibiotic days 6.3 (3.1)¶ 6 7.6 (2.6)¶ 8
Total number of antibiotic days (intravenous plus oral) 7.3 (3.6) 6.5 8.3 (2.7) 8.0
Number (%) of successful episodes 72 (100%) 72 (100%)
*Signiﬁcantly different, P = .004.
†Signiﬁcantly different, P < .001.
‡Signiﬁcantly different, P = .001.
§Signiﬁcantly different, P = .002.
||Signiﬁcantly different, P = .015.
¶Signiﬁcantly different, P = .008.
Abbreviations: PRBC, packed red blood cells;TPN, total parenteral nutrition.
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the hospital and 0 days in home care, while children
in the home-care-based group spent a median of
0 days in the hospital and 7 days of home-care treat-
ment, respectively (p < .001). All patients success-
fully recovered from their FN episodes.
Health-care resource consumption amounts were
greater (p < .01) in the hospital-based group, par-
ticularly for physician visits, chest radiographs, 
laboratory serologic tests, and support with total
parenteral nutrition. A comparison of the hospital
and home-care-based groups, respectively, revealed
signiﬁcant differences (p < .01) in the utilization 
of ancillary tests such as chest radiographs (29 vs.
8%), urinalyses (29 vs. 7%), computerized tomog-
raphy (CT) scans (11 vs. 0%), and aminoglycoside
or vancomycin concentration studies (47 vs. 1%).
As expected, children managed in the home-care-
based group received more clinic and home-care
nursing visits. When only patients receiving ﬁlgras-
tim were compared between these two treatment
settings, results did not change; all of these differ-
ences remained signiﬁcant (p < .01).
Charges associated with health-care utilization
were compared (Table 3). The three most expensive
health-care resources in the hospital-based group
were hospitalization, antibiotic use, and ﬁlgrastim
charges. The three highest expenses in the home-
care-based group were antibiotic use, home-care
visits, and ﬁlgrastim charges. Charges for studies
(radiographs and CT scans) and total laboratory
charges did not have a large impact upon the total
charge in the either setting. The difference in total
charges per episode between the two groups was
$5155 and $3499, for mean and median charges,
respectively. Thus, total savings (US$1998) associ-
ated with home-care management of 72 episodes 
of FN was $371,160, using mean values, and
$251,928, using median values.
The prevalence of positive blood cultures was
signiﬁcantly higher (P = .012) in the hospital-based
group (n = 22, 30.6%) compared to the home-care-
based group (n = 8, 11.1%). The most common
organisms encountered in the hospital-based group
were Streptococcus (n = 7), Staphylococcus (n = 4),
and Pseudomonas (n = 4). In the home-care-based
group, only two cultures were positive for Strepto-
coccus spp. and all other organisms were repre-
sented by one species each.
Of the 72 FN episodes treated in the hospital-
based group, 61 (85%) were treated with cef-
tazidime and vancomycin, while only 8 (11%) FN
episodes in the home-care-based group were
managed with this combination. Vancomycin was
more frequently used initially in the hospital-based
FN group, reﬂecting a more aggressive initial treat-
ment philosophy. Aminoglycosides were used more
commonly (P < .001) in the hospital-based group
(19 vs. 1%), as was acyclovir (11 vs. 1%), and 
ﬂuconazole (17 vs. 0%). Amphotericin (8%), naf-
cillin (7%), and ceftriaxone (6%) were used only in
the hospital-based cohort.
We evaluated the sensitivity of our results
Table 3 Charges, adjusted to 1998 US dollars, associated with health-care resources
Hospital-based Home-care-based 
treatment (UAMC) treatment (UNM)
Health-care item Mean $ (SD) Median Mean $ (SD) Median
Blood cultures 127 (35) 150* 142 (24) 150*
All cultures 279 (96) 250† 215 (38) 200†
Microbiology 23 (60) 0† 0 0†
Complete blood counts 121 (60) 198‡ 89 (32) 148‡
Serum chemistries 266 (248) 182† 83 (104) 81†
Clinic visits 24 (25) 0† 83 (67) 100†
Home-care days 456 (691) 0† 1529 (670) 1554†
Hospital days 5,826 (2,810) 5460† 101 (496) 0†
Antibiotics 2,375 (2,452) 1526§ 2523 (1332) 2523§
Platelet transfusions 75 (84) 84 58(91) 42
PRBC transfusions 112 (126) 126 88(136) 63
Physician visits 460 (230) 420† 29 (69) 0†
TPN 269 (511) 0† 32 (272) 0†
Aminoglycoside levels 18 (42) 0 1(4) 0
Vancomycin levels 26 (41) 0† 0 0†
Chest X-ray 54 (85) 0† 12 (38) 0†
CT 110 (297) 0‡ 0 0‡
Intensive care unit days 18 (150) 0 141(695) 0
Filgrastim 622 (878) 451† 1023 (740) 1085†
Total charges 11,236 (6,372) 9392† 6081 (2653) $5893†
*Signiﬁcantly different, P = .004.
†Signiﬁcantly different, P < .001.
‡Signiﬁcantly different, P = .001.
§Signiﬁcantly different, P = .019.
Abbreviations: PRBC, packed red blood cells;TPN, total parenteral nutrition.
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(Fig. 1). The results were most affected by decreas-
ing median total charges in the hospital-based
group to the lower quartile. Even in this scenario,
savings with home care was approximately $1100
per treatment. Since antibiotic and ﬁlgrastim
charges were higher among home-care patients
these resources are shown on the left side of $0 
in Fig. 1. Sensitivity analyses magnify the lower
charges in the hospital setting for these resources.
Removing charges for these resources from total
charges increased relative savings with home care.
Removing lab charges had minimal effect, with
slightly decreased savings in the home-care 
population.
In our break-even sensitivity analysis, median
home-care charges were found to be 62.7% of 
hospital charges. In our break-even analysis of hos-
pitalization and home-care costs avoided, we used
total charges and assumed that health-care
resources were equally distributed each day of 
hospitalization. We found that hospitalization and
follow-up home care (in the hospital-based group)
would have to decrease by 3.4 and 1.2 days, respec-
tively, to achieve charges equivalent to those
observed in the home-care-based group.
Discussion
Our results indicate that management of children
with low-risk chemotherapy-induced FN with home
care can result in signiﬁcant savings of health-care
resources without adversely impacting patient out-
comes. Recovery rates were 100% in both groups
and there were no signiﬁcant differences in inten-
sive care support or total number of days of antibi-
otic therapy. Although statistically signiﬁcant, we
do not consider the 1.3 additional days of intra-
venous antibiotic therapy among home-care-
managed FN patients to be clinically signiﬁcant. It
may have been due to number of days of intra-
venous antibiotics delivered periodically to the
home, usually a 2- to 3-day supply. The tendency
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of home-care nurses may have been to use up the
remaining intravenous doses, rather than requesting
discontinuance.
As expected, the driver for higher charges was
hospital days. Use of several other health-care
resources was signiﬁcantly greater in the hospital
setting. This may have occurred because of antici-
pation of complications in a potentially fragile
patient population. Laboratory services, imaging
services, and pediatric subspecialists were more
readily available in the hospital setting, also possi-
bly contributing to increased utilization.
In our analyses we estimated charges by apply-
ing uniform unit charges to hospital and home
health-care resource utilization amounts. We chose
this method to assure that differences between the
two medical centers’ pricing methods were excluded
from the results. Our results are based on 1998
values; current prices (2002) at the University of
New Mexico are 38.6% higher. In Table 2 mean
and median quantities of resources used per treat-
ment episode are shown. These data could be used,
along with charges for current antibiotic regimens,
to estimate current charges for home and hospital
treatment of low-risk FN at another facility. Esti-
mates should focus on antibiotic and ﬁlgrastim
charges plus, as appropriate, hospital charges or
home-care charges. We note that these variables
accounted for 79% of total median charges among
hospital-managed FN patients and 88% of total
median charges among home-care-managed FN
patients.
The mean number of inpatient days and inci-
dence of positive blood cultures among our 
hospital-based FN episodes was similar to those
previously reported for childhood FN [11,20,21].
We postulate two reasons for a lower incidence of
positive blood cultures in the home-care-based
group. First, the number of the health-care
providers who access central lines may be higher in
the hospital setting, predisposing patients to higher
rates of positive blood cultures. Second, the 
hospital-based FN group received most of their
courses of myelosuppressive chemotherapy on the
inpatient ward compared to primarily home-
care-based chemotherapy courses with the 
home-care-based FN group. Nosocomially acquired
colonization may have been more prevalent among
patients treated with prior chemotherapy in the 
hospital.
We tested this hypothesis among a follow-up
sample of UNM pediatric patients subsequently
treated for FN due to chemotherapy (n = 29).
Because of administrative changes by local managed
care providers, payment for home-care chemother-
apy was discontinued for the only local home-care
agency with adequate training and expertise in
delivery of home-care chemotherapy. Therefore, our
pediatric oncology treatment team shifted immuno-
suppressive chemotherapy administration back to
the inpatient ward. Among this follow-up sample,
the rate of positive blood cultures during FN
episodes was 20.6% (6 of 29 patients). Further-
more, the average hospital stay during chemo-
therapy treatment was signiﬁcantly longer among
patients who developed positive blood cultures
(2.9 ± 1.8 vs. 1.8 ± 1.8 days, P = .044). This result
suggests that hospital-based chemotherapy and its
duration are related to positive blood cultures in
subsequent FN episodes.
To remove the potential impact of positive cul-
tures, we reanalyzed our data using only culture-
negative FN episodes from each group. Signiﬁcantly
lower costs were again found among FN episodes
managed in the home-care setting (P < .01). We also
note that the depth, duration, and biological nature
of the chemotherapy-induced, low-risk FN episodes
included in this study were similar in the two groups
(Table 1). The total number of days of antibiotic
treatment was greater for the home-care patients,
although the difference was not signiﬁcant
(Table 2).
Our results were stable across all sensitivity
analyses. Savings were not signiﬁcantly affected
when charges for antibiotic therapy, ﬁlgrastim, 
and laboratory tests were removed (Fig. 1),
although these resources were utilized at different
rates between the treatment settings. Children
treated for FN in the home-care setting incurred
higher charges for ﬁlgrastim and antibiotics, but
approximately 6 days of hospitalization were
avoided. Our sensitivity analyses verify that these
differences in practice patterns did not account for
savings associated with home-care treatment. Use of
ﬁlgrastim may have been a factor contributing to
physicians’ willingness to implement a primarily
home-care-based FN treatment program, because it
provided some assurance that the period of severe
neutropenia would be signiﬁcantly abbreviated
[22,23]. The UNM home-care program was initi-
ated after this cytokine became available.
Our pediatric oncology/hematology team would
only consider home-care-based FN treatment when
the following four prerequisites were established: 1)
criteria for low-risk FN; 2) simpliﬁed drug delivery
systems that allow patients’ families to administer
antibiotics with minimal training; 3) a staff of
highly skilled home-care nurses who were available
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24 hours per day; and 4) a strictly applied protocol
of emergency contacts and follow-up procedures.
We believe that home-care-based FN should only be
considered with these prerequisites in place.
We acknowledge that lack of random assignment
of patients to hospital- or home-care-based FN
treatment is a limitation of this study. However, our
comparison group was similar demographically and
in regard to depth of neutropenia. In both groups
we included all patients meeting the inclusion crite-
ria during our study periods. The period was longer
for UNM because of a smaller total population of
pediatric oncology patients. To address this limita-
tion, we reanalyzed our data with only 1994
through 1997 data from UNM institutions (n = 36).
We found the same signiﬁcant differences with this
partial data set. Once home-care treatment was suc-
cessfully implemented at UNM, both children 
and parents preferred it to avoid hospitalization.
Furthermore, the pediatric hematology/oncology
programs at UAMC and UNM used similar
chemotherapy regimens and both institutions were
afﬁliates of the Pediatric Oncology Group. Early
discharge for children with low-risk FN is now
being employed at some treatment centers [9,11].
Among UAMC (hospital-based FN managed)
patients, 18 (25%) were discharged to home-care
before completion of FN management. Home
health charges were included in health total costs
among hospital-based patients. This substitution
for the last few days of hospital FN management
likely avoids some charges, but our home-based
care group still had signiﬁcantly lower charges. We
compared patients from UAMC who did versus
those did not receive some home care. Total median
costs were approximately $300 greater for those
transferred to home care, while mean costs were
approximately $2500 less. These differences were
not statistically signiﬁcant; therefore, this care
appears to represent substitution for hospital care
rather than additional care.
We note two differences in the two groups: 
more frequent initial use of vancomycin and more
leukemias and lymphomas for hospital-based FN-
managed patients. In a review of the literature
regarding management of FN, it was concluded 
that no difference in outcome is associated with 
the initial use of vancomycin [24]. The authors 
concluded that unless there is a high prevalence 
of Staphylococcus epidermidis bacteremia, van-
comycin need not be given during initial manage-
ment of FN. Regarding types of tumors, other
researchers have found no difference in severity or
outcome of FN between patients with leukemias
and solid tumors [25]. The authors reported similar
rates of depth and duration of neutropenia, as well
no signiﬁcant differences in course or outcome of
FN [25]. We note that initial ANC values are very
similar between the two comparison groups
(Table 1.)
We stress that the outpatient management of
childhood FN be tailored to individual patients, to
the capabilities of a particular home-care agency,
and to the relationship between the agency and the
pediatric oncology center. While the savings and
intangible beneﬁts are many, the child’s safety is
paramount. Although much of medical care is shift-
ing away from hospital-based practice, many insti-
tutions may not have the necessary infrastructure 
to provide adequate home-care-based FN manage-
ment. When managed care organizations subse-
quently changed the preferred home-care provider,
we were no longer able to deliver safe home-care
chemotherapy or FN treatment. In addition,
complex psychosocial problems among patients and
their families, such as lack of resources in the home
(i.e., proper sanitation, 24-hour supervision, refrig-
erated storage) or unstable medical problems miti-
gate against home care even if a competent agency
is available.
Conclusions
Our study is the ﬁrst to enumerate speciﬁc resource
utilization for FN management of children in a
home-care setting [9–12]. We found that home-care
treatment of low-risk FN can be implemented safely
to yield substantial savings in health-care resources
provided that there is close supervision by a 
pediatric oncology center. We demonstrated lower
charges in the home-care-based treatment group.
We recommend that future studies incorporate
analyses of nonmedical resources and outcomes,
such as indirect costs, lost wages from missed days
of work, and quality of life for both children and
their parents. Only through addressing these addi-
tional outcomes can the full impact of home-care-
based treatment of FN be fully understood.
This study was funded by Amgen, Inc., Thousand Oaks,
CA.
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